AxoGen Inc. (AXGN) reported its fourth-quarter 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.07 against a forecast of $0.03. The company's revenue for the quarter reached $49.4 million, exceeding the anticipated $47.58 million. This positive performance led to a premarket stock price increase of 2.61%, reaching $18.48 per share. According to InvestingPro, the company, currently valued at approximately $792 million, appears to be trading near its Fair Value, with analysts maintaining a strong buy consensus.
Key Takeaways
- AxoGen's Q4 2024 EPS of $0.07 beat forecasts by over 133%.
- Revenue for Q4 2024 grew by 15.1% year-over-year to $49.4 million.
- Premarket stock price rose by 2.61% following the earnings announcement.
- The company is focusing on expanding its nerve repair algorithm across multiple markets.
- AxoGen projects a 15-17% revenue growth for 2025.
Outlook & Guidance
For 2025, AxoGen anticipates revenue growth of 15-17% and aims to maintain a gross margin between 73-75%. The company expects to be cash flow positive throughout the year and plans to continue investing in innovation and market development. Future projections include a focus on expanding its sales force and exploring new market opportunities, such as prostatectomy nerve repair.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.